The study aims to evaluate the tolerability of multiple-dose topical dapaconazole tosylate, a new imidazole antiftmgal drug, in healthy vohmteers. Twenty-four healthy vohmteers (12 men) with skin pigmentation classified as I-III in the Fitzpatrick scale emolled in this open-label, two-treatment study with daily application of 40 mg of dapaconazole for 14 consecutive days. Drug application was monitored by a physician and photographs were taken before and 1 h after application to evaluate possible dermatological reactions. Medical evaluations including physical examination, laboratory tests and electrocardiograms were performed to evaluate possible systemic adverse events. To evaluate systemic dapaconazole absorption blood samples were collected before and 2, 4 and 6 h after products application on the first day of treatment. The same occwred in days 7 and 13, but an extra 24 h sample was collected after application of the products. Dapaconazole plasma levels were measured by high-performance liquid chromatography coupled to tandem mass spectrometry. No vohmteers had dermatological reactions to the formulations. Only one blood sample had detectable levels of dapaconazole (0.23 ng mL-1). One volunteer presented hypertriglyceridemia108507512Alexandra, J.F., Pautas, E., Gouin-Thibault, I., Siguret, V., Loriot, M.A., Over anticoagulation with cownarin and cutaneous azole therapy (2008) Ann. Internal Me<Checkcomponent>D</Checkcomponent>., 148, pp. 633-635Ali, S.M., Brodell, R.I., Balkrishnan, R., Feldman, S.R., Poor adherence to treatments: A fundamental principle of dermatology (2007) Arch. Dermatol., 143, pp. 912-915Botter, A.A., Topical treatment of nail and skin infections with miconazole, a new broad-spectnnn antimycotic (1971) Mykoses, 14, pp. 187-191Broos, N., Van Puijenbroek, E.P., Interaction between topical miconazole and colllllarins (2010) Eur. J. Clin. Pharmacal., 66, pp. 1171-1172Plempel. 1972. [Synthesis and properties of clotrimazole and other antimycotic 1-triphenylmethylimidazoles] Armeirnittelforschung, 22, pp. 1260-1272. , Buchel. K.H., W. Draber, E. Regel and M, In GermanCanton, E., Peman, J., Quindos, G., Eraso, E., Miranda-Zapico, I., Prospective multicenter study of the epidemiology, molecular identification and antifrmgal susceptibility of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis isolated from patients with candidemia (2011) Antimicrob. Agents Chemother., 55, pp. 5590-5596Courtney, R., Pai, S., Laughlin, M., Lim, J., Batra, V., Pharmacokinetics, safety and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob (2003) Agents Chemother., 47, pp. 2788-2795De Lima Barros, M.B., Schubach, A.O., De Oliveira, R., Martins, E.B., Teixeira, J.L., Wanke, B., Treatment of cutaneous sporotrichosis with itraconazole-study of 645 patients. (2011) Clin. Infect. Di<Checkcomponent>S</Checkcomponent>, 52, pp. e200-e206De Moraes, F.C., Bittencowt, S.F., Perissutti, E., Frencentese, F., Arruda, A., Quantification of dapaconazole in hlllllan plasma usmg high-performance liquid chromatography coupled to tandem mass spectrometry: Application to a phase I study. J (2014) Chromatogr., 958, pp. 102-107Debruyne, D., Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses (1997) Clin. Pharmacokinet., 33, pp. 52-77Del Rosso, J.Q., Reece, B., Smith, K., Miller, T., Efinaconazole 10% solution: A new topical treatment for onychomycosis. Contact sensitization and skin irritation potential (2013) J. Clin. Aesthetic Dermatol., 6, pp. 20-24Dostrovsky, A., Raubitschek, F., Paz, Z.E., Axelrad, B., The treatment of Tinea capitis with oral potassiwn iodide (1960) J. Invest. Dermatol., 34, pp. 347-349Eichenfield, L.F., Bogen, M.L., Absorption and efficacy of miconazole nitrate 0.25% ointment in infants with diaper dermatitis (2007) J. Drugs Dermatol., 6, pp. 522-526Faller, M.A., Messer, S.A., Moet, G.J., Jones, R.N., Castanheira, M., Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifrmgal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial SillVeillance Program (2008-2009) (2011) Int. J. Antimicrob. Agents, 38, pp. 65-69Fitzpatrick, T.B., The validity and practicality of srm-reactive skin types I through VI. Arch (1988) Dermatol., 124, pp. 869-871Galatti, L., Lazzaglia, G.L., Greco, A., Sessa, E., Cricelli, C., Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: A four-year analysis from Italian general practice. (2007) Phannacoepidemiol.Drug Saf., 16, pp. 422-428Ghannoum, A.M., Rice, L.B., Antifungal agent. Mode of action, mechanisms of resistance and correlation of these mechanisms with bacterial resistance (1999) Clin. Microbial. Rev., 12, pp. 501-517Jegasothy, B.V., Fakes, G.E., Oxicomzole nitrate: Pharmacology, efficacy and safety of a new imidazole antifungal agent (1991) Clin. Ther., 13, pp. 126-141Kepler, A.F., Sacurai, S.L., Zairn, M.H., Touzarirn, C., (2012) Benzyl Aralkyl Ether Compounds. Method for Preparing Same, Intermediate Compormds, Use of Said Compormds, Method for Treatment And/Or Prevention, Pharmaceutical Composition and Medicament Containing Same, , http://www.google.com/patents/US20120196908, U.S. Patent Publication No. US20120196908 Al. August 2. 2012Leiste, D., Brann, W., Fegeler, W., Fegeler, K., Stary, A., A double-blind clinical trial of fenticonazole (2%) spray versus naftifine (1%) spray in patients with cutaneous mycoses (1989) Cwr. Med. Res. Opin, 11, pp. 567-575Lockhart, S.R., Cleveland, N.I., Farley, M.M., Harrison, L.H., Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011 (2012) J. Clin. Microbial., 50, pp. 3435-3442Radloff, C., Koch, D., Schaumann, R., Epidemiology and antifllllgal resistance in invasive candidiasis (2011) Eur. J. Med. Re<Checkcomponent>S</Checkcomponent>., 16, pp. 187-195Rollman, O., Jameson, S., Lithell, H., Effects of long-term ketoconazole therapy on serum lipid levels (1985) Eur. J. Clin. Pharmacal., 29, pp. 241-245Sharma, A., Saple, D.G., Surjushe, A., Rao, G., Kura, M., Efficacy and tolerability of sertaconazole nitrate 2% cream vs. Miconazole in patients with cutaneous dermatophytosis (2011) Mycoses, 54, pp. 217-222Sternberg, S., The emerging fnngal threat (1994) Science, 266, pp. 1632-1634Stevens, R.E., Konsil, J., Verrill, S.S., Roy, P., Desai, P.B., Upmalis, D.H., Cone, F.L., Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults (2002) J. Clin. Pharmacal., 42, pp. 52-60Suschka, S., Fladung, B., Merk, H.F., Clinical comparison of the efficacy and tolerability of once daily Canesten® with twice daily Nizoral® (clotrimazole 1% cream vs. Ketoconazole 2% cream) during a 28-day topical treatment of interdigital tinea pedis (2002) Mycoses, 45, pp. 91-96Thienpont, D., Van Cutsem, J., Van Nueten, J.M., Niemegeers, C.J., Marsboom, R., Biological and toxicological properties of econazole, a broad­ spectrum antimycotic (1975) Armeimittelforschtmg, 25, pp. 224-230Tucker, R.M., Haq, Y., Denning, D.W., Stevens, D.A., Adverse events associated with itraconazole in 189 patients on chronic therapy (1990) J Antimicrob. Chemother., 26, pp. 561-566Urmabe, H., Nagashima, T., Mechanism of antiftmgal action of potassiwn iodide on sporotrichosis (1969) Int. J. Dermatol., 8, pp. 36-39Verweij, P.E., Warris, A., Update on antifungal resistance m children: Epidemiology and recommendations (2013) Pediatr. Infect. Dis. J., 32, pp. 556-557WMA, World medical association declaration of Helsinki-Ethical principles for medical research involving hwnan subjects (2008) World Med. J., 54, pp. 120-124Watanabe, S., Nishikawa, H.T., Takiuchi, I., Higashi, N., Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis-comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study (2007) Mycoses, 50, pp. 35-40Weinberg, J.M., Increasing patient adherence in antiftmgal infection treatment: Once-daily dosing of sertaconazole (2009) J. Clin. Aesthetic Dermatol., 2, pp. 38-42Wey, P.F., Petieans, F., Lions, C., Ould-Ahmed, M., Escannent, J., Laryngeal dyspnea in relation to an interaction between acenocownarol and topical econazole lotion (2008) Am. J. Geriatr. Phannacother., 6, pp. 173-177Whiffen, A.J., Bohonos, N., Emerson, R.L., The production of an antifrmgal antibiotic by Streptomyces griseus (1946) J. Bacterial., 52, pp. 610-611Yu, D.T., Peterson, J.F., Seger, D.L., Gerth, W.C., Bates, D.W., Frequency of potential azole diug­ drug interactions and consequences of potential fluconazole drug interactions. Phannacoepidemiol (2005) Drug Saf., 14, pp. 755-767